Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2020

18.04.2020 | Topic Review

Advances in the management of primary bone sarcomas of the skull base

verfasst von: Idara Edem, Franco DeMonte, Shaan M. Raza

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Skull base primary malignancies represent a heterogeneous group of histologic diagnoses and sarcomas of the skull base are specific malignant tumors that arise from mesenchymal cells and can be classified by site of origin into bony and soft tissue sarcomas. The most common bony sarcomas include: chondrosarcoma, osteosarcoma, chordoma, Ewing’s sarcoma. Given the relative rarity of each histologic diagnosis, especially in the skull base, there is limited published data to guide the management of patients with skull base sarcomas. An electronic search of the literature was performed to obtain key publications in the management of bony sarcomas of the skull base published within the last decade. This article is thus a review of the multi-disciplinary management principles of primary bony sarcomas of the skull base. Of note, there have been several recent advancements in the realm of skull base sarcoma management that have resulted in improved survival. These include advances in: imaging and diagnostic techniques, surgical techniques that incorporate oncologic surgical principles, conformal radiation paradigms and targeted systemic therapies. Early access to coordinated multi-disciplinary subspecialty care immediately at suspicion of diagnosis has further improved outcomes. There are several ongoing trials in the realms of radiation therapy and systemic therapy that will hopefully provide further insight about the optimal management of bony sarcomas of the skull base.
Literatur
1.
Zurück zum Zitat Fletcher CD et al (2013) WHO classification of tumors of soft tissue and bone, 4th edn. IARC Press, Lyon Fletcher CD et al (2013) WHO classification of tumors of soft tissue and bone, 4th edn. IARC Press, Lyon
2.
Zurück zum Zitat Carlson ML et al (2016) Petroclival chondrosarcoma: a multicenter review of 55 cases and new staging system. Otol Neurotol 37(7):940–950PubMed Carlson ML et al (2016) Petroclival chondrosarcoma: a multicenter review of 55 cases and new staging system. Otol Neurotol 37(7):940–950PubMed
3.
Zurück zum Zitat Freeman JL et al (2018) Impact of early access to multidisciplinary care on treatment outcomes in patients with skull base chordoma. Acta Neurochir (Wien) 160(4):731–740 Freeman JL et al (2018) Impact of early access to multidisciplinary care on treatment outcomes in patients with skull base chordoma. Acta Neurochir (Wien) 160(4):731–740
4.
Zurück zum Zitat NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Bone Cancer, Version 1.2020. 2019. Accessed 11 Sept 2019 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Bone Cancer, Version 1.2020. 2019. Accessed 11 Sept 2019
5.
Zurück zum Zitat Bell D et al (2016) Whole-transcriptome analysis of chordoma of the skull base. Virchows Arch 469(4):439–449PubMed Bell D et al (2016) Whole-transcriptome analysis of chordoma of the skull base. Virchows Arch 469(4):439–449PubMed
6.
Zurück zum Zitat Frezza AM et al (2019) Chordoma: update on disease, epidemiology, biology and medical therapies. Curr Opin Oncol 31(2):114–120PubMed Frezza AM et al (2019) Chordoma: update on disease, epidemiology, biology and medical therapies. Curr Opin Oncol 31(2):114–120PubMed
7.
Zurück zum Zitat Kitamura Y, Sasaki H, Yoshida K (2017) Genetic aberrations and molecular biology of skull base chordoma and chondrosarcoma. Brain Tumor Pathol 34(2):78–90PubMed Kitamura Y, Sasaki H, Yoshida K (2017) Genetic aberrations and molecular biology of skull base chordoma and chondrosarcoma. Brain Tumor Pathol 34(2):78–90PubMed
8.
Zurück zum Zitat Raza SM et al (2020) Surgical management of primary skull base osteosarcomas: impact of margin status and patterns of relapse. Neurosurgery 86(1):E23–E32PubMed Raza SM et al (2020) Surgical management of primary skull base osteosarcomas: impact of margin status and patterns of relapse. Neurosurgery 86(1):E23–E32PubMed
9.
Zurück zum Zitat Raza SM et al (2018) Multimodality management of recurrent skull base chordomas: factors impacting tumor control and disease-specific survival. Oper Neurosurg (Hagerstown) 15(2):131–143 Raza SM et al (2018) Multimodality management of recurrent skull base chordomas: factors impacting tumor control and disease-specific survival. Oper Neurosurg (Hagerstown) 15(2):131–143
10.
Zurück zum Zitat Koutourousiou M et al (2012) Endoscopic endonasal approach for resection of cranial base chordomas: outcomes and learning curve. Neurosurgery 71(3):614–624PubMed Koutourousiou M et al (2012) Endoscopic endonasal approach for resection of cranial base chordomas: outcomes and learning curve. Neurosurgery 71(3):614–624PubMed
11.
Zurück zum Zitat Sen C et al (2010) Clival chordomas: clinical management, results, and complications in 71 patients. J Neurosurg 113:1059–1071PubMed Sen C et al (2010) Clival chordomas: clinical management, results, and complications in 71 patients. J Neurosurg 113:1059–1071PubMed
12.
Zurück zum Zitat Raza SM et al (2017) Multimodality treatment of skull base chondrosarcomas: the role of histology specific treatment protocols. Neurosurgery 81(3):520–530PubMed Raza SM et al (2017) Multimodality treatment of skull base chondrosarcomas: the role of histology specific treatment protocols. Neurosurgery 81(3):520–530PubMed
13.
Zurück zum Zitat Sekhar L et al (2001) Chordomas and chondrosarcomas of the skull base: results and complications of surgical management. Neurosurg Focus 10(3):1–4 Sekhar L et al (2001) Chordomas and chondrosarcomas of the skull base: results and complications of surgical management. Neurosurg Focus 10(3):1–4
14.
Zurück zum Zitat Irish JC et al (1994) Tumors of the skull base: outcome and survival analysis of 77 cases. Head Neck 16(1):3–10PubMed Irish JC et al (1994) Tumors of the skull base: outcome and survival analysis of 77 cases. Head Neck 16(1):3–10PubMed
15.
Zurück zum Zitat Chibbaro S et al (2014) Endoscopic endonasal approach in the management of skull base chordomas-clinical experience on a large series, technique, outcome and pitfalls. Neurosurg Rev 37(2):217–225PubMed Chibbaro S et al (2014) Endoscopic endonasal approach in the management of skull base chordomas-clinical experience on a large series, technique, outcome and pitfalls. Neurosurg Rev 37(2):217–225PubMed
16.
Zurück zum Zitat Raza SM et al (2018) Site-specific considerations in the surgical management of skull base chondrosarcomas. Oper Neurosurg (Hagerstown) 14(6):611–619 Raza SM et al (2018) Site-specific considerations in the surgical management of skull base chondrosarcomas. Oper Neurosurg (Hagerstown) 14(6):611–619
17.
Zurück zum Zitat Mehta GU et al (2018) Endoscopic endonasal transpterygoid transnasopharyngeal management of petroclival chondrosarcomas without medial extension. J Neurosurg 131:184–191PubMed Mehta GU et al (2018) Endoscopic endonasal transpterygoid transnasopharyngeal management of petroclival chondrosarcomas without medial extension. J Neurosurg 131:184–191PubMed
18.
Zurück zum Zitat Moussazadeh N et al (2015) Endoscopic endonasal resection of skull base chondrosarcomas: technique and early results. J Neurosurg 122(4):735–742PubMed Moussazadeh N et al (2015) Endoscopic endonasal resection of skull base chondrosarcomas: technique and early results. J Neurosurg 122(4):735–742PubMed
19.
Zurück zum Zitat Hanasono MM et al (2011) Skull base reconstruction: an updated approach. Plast Reconstruct Surg 128(3):675–686 Hanasono MM et al (2011) Skull base reconstruction: an updated approach. Plast Reconstruct Surg 128(3):675–686
20.
Zurück zum Zitat Guadagnolo BA et al (2009) Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment. Cancer 115(14):3262–3270PubMed Guadagnolo BA et al (2009) Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment. Cancer 115(14):3262–3270PubMed
21.
Zurück zum Zitat Simon F et al (2018) Surgery and protontherapy in Grade I and II skull base chondrosarcoma: a comparative retrospective study. PLoS ONE 13(12):e0208786PubMedPubMedCentral Simon F et al (2018) Surgery and protontherapy in Grade I and II skull base chondrosarcoma: a comparative retrospective study. PLoS ONE 13(12):e0208786PubMedPubMedCentral
22.
Zurück zum Zitat De Amorim Bernstein K, DeLaney T (2016) Chordomas and chondrosarcomas—the role of radiation therapy. J Surg Oncol 114(5):564–569PubMed De Amorim Bernstein K, DeLaney T (2016) Chordomas and chondrosarcomas—the role of radiation therapy. J Surg Oncol 114(5):564–569PubMed
23.
Zurück zum Zitat Demizu Y et al (2017) Proton beam therapy for bone sarcomas of the skull base and spine: a retrospective nationwide multicenter study in Japan. Cancer Sci 108(5):972–977PubMedPubMedCentral Demizu Y et al (2017) Proton beam therapy for bone sarcomas of the skull base and spine: a retrospective nationwide multicenter study in Japan. Cancer Sci 108(5):972–977PubMedPubMedCentral
24.
Zurück zum Zitat Santoni R et al (1998) Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull. Int J Radiat Oncol Biol Phys 41(1):59–68PubMed Santoni R et al (1998) Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull. Int J Radiat Oncol Biol Phys 41(1):59–68PubMed
25.
Zurück zum Zitat Weber DC et al (2016) Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. Radiother Oncol 120(1):169–174PubMed Weber DC et al (2016) Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. Radiother Oncol 120(1):169–174PubMed
26.
Zurück zum Zitat Feuvret L et al (2016) Efficacy and safety of adjuvant proton therapy combined with surgery for chondrosarcoma of the skull base: a retrospective, population-based study. Int J Radiat Oncol Biol Phys 95(1):312–321PubMed Feuvret L et al (2016) Efficacy and safety of adjuvant proton therapy combined with surgery for chondrosarcoma of the skull base: a retrospective, population-based study. Int J Radiat Oncol Biol Phys 95(1):312–321PubMed
27.
Zurück zum Zitat Baumann BC et al (2020) Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer. JAMA Oncol 6(2):237–246PubMed Baumann BC et al (2020) Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer. JAMA Oncol 6(2):237–246PubMed
28.
Zurück zum Zitat Uhl M et al (2014) High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results. Cancer 120(10):1579–1585PubMed Uhl M et al (2014) High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results. Cancer 120(10):1579–1585PubMed
29.
Zurück zum Zitat Frisch S, Timmermann B (2017) The evolving role of proton beam therapy for sarcomas. Clin Oncol (R Coll Radiol) 29(8):500–506 Frisch S, Timmermann B (2017) The evolving role of proton beam therapy for sarcomas. Clin Oncol (R Coll Radiol) 29(8):500–506
30.
Zurück zum Zitat McDonald M et al (2016) Influence of residual tumor volume and radiation dose coverage in outcomes for clival chordoma. Int J Radiat Oncol Biol Phys 95(1):304–311PubMed McDonald M et al (2016) Influence of residual tumor volume and radiation dose coverage in outcomes for clival chordoma. Int J Radiat Oncol Biol Phys 95(1):304–311PubMed
31.
Zurück zum Zitat Austin-Seymour M et al (1989) Fractionated proton radiotherapy of chordoma and low-grade chondrosarcoma of the base of the skull. J Neurosurg 70(1):13–17PubMed Austin-Seymour M et al (1989) Fractionated proton radiotherapy of chordoma and low-grade chondrosarcoma of the base of the skull. J Neurosurg 70(1):13–17PubMed
32.
Zurück zum Zitat Terahara A et al (1999) Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. Int J Radiat Oncol Biol Phys 45:351–358PubMed Terahara A et al (1999) Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. Int J Radiat Oncol Biol Phys 45:351–358PubMed
33.
Zurück zum Zitat Wagner MJ et al (2016) Chemotherapy for bone sarcoma in adults. J Oncol Pract 12(3):208–216PubMed Wagner MJ et al (2016) Chemotherapy for bone sarcoma in adults. J Oncol Pract 12(3):208–216PubMed
34.
Zurück zum Zitat Colia V, Stacchiotti S (2017) Medical treatment of advanced chordomas. Eur J Cancer 83:220–228PubMed Colia V, Stacchiotti S (2017) Medical treatment of advanced chordomas. Eur J Cancer 83:220–228PubMed
35.
Zurück zum Zitat Stacchiotti S, Longhi A, Ferraresi V (2012) Phase II study of imatinib in advanced chordoma. J Clin Oncol 30:914–920PubMed Stacchiotti S, Longhi A, Ferraresi V (2012) Phase II study of imatinib in advanced chordoma. J Clin Oncol 30:914–920PubMed
36.
Zurück zum Zitat Stacchiotti S et al (2013) Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol 24:1931–1936PubMed Stacchiotti S et al (2013) Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol 24:1931–1936PubMed
37.
Zurück zum Zitat Bell AH et al (2018) Transcriptome comparison identifies potential biomarkers of spine and skull base chordomas. Virchows Arch 472(3):489–497PubMed Bell AH et al (2018) Transcriptome comparison identifies potential biomarkers of spine and skull base chordomas. Virchows Arch 472(3):489–497PubMed
38.
Zurück zum Zitat Stacchiotti S, Sommer J, C.G.C. Group (2015) Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol 16:e71–e83PubMed Stacchiotti S, Sommer J, C.G.C. Group (2015) Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol 16:e71–e83PubMed
39.
Zurück zum Zitat Thanindratarn P et al (2019) Advances in immune checkpoint inhibitors for bone sarcoma therapy. J Bone Oncol 15:100221PubMedPubMedCentral Thanindratarn P et al (2019) Advances in immune checkpoint inhibitors for bone sarcoma therapy. J Bone Oncol 15:100221PubMedPubMedCentral
40.
Zurück zum Zitat Patel SS, Schwab JH (2016) Immunotherapy as a potential treatment for chordoma: a review. Curr Oncol Rep 18(9):55PubMed Patel SS, Schwab JH (2016) Immunotherapy as a potential treatment for chordoma: a review. Curr Oncol Rep 18(9):55PubMed
41.
Zurück zum Zitat Evans L et al (2020) Salvage therapy for local progression following definitive therapy for skull base chordomas: is there a role for stereotactic radiosurgery? J Neurol Surg B 81:97–106 Evans L et al (2020) Salvage therapy for local progression following definitive therapy for skull base chordomas: is there a role for stereotactic radiosurgery? J Neurol Surg B 81:97–106
43.
Zurück zum Zitat Kano H et al (2015) Skull base chondrosarcoma radiosurgery: report of the North American Gamma Knife Consortium. J Neurosurg 123(5):1268–1275PubMed Kano H et al (2015) Skull base chondrosarcoma radiosurgery: report of the North American Gamma Knife Consortium. J Neurosurg 123(5):1268–1275PubMed
Metadaten
Titel
Advances in the management of primary bone sarcomas of the skull base
verfasst von
Idara Edem
Franco DeMonte
Shaan M. Raza
Publikationsdatum
18.04.2020
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-020-03497-6

Weitere Artikel der Ausgabe 3/2020

Journal of Neuro-Oncology 3/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.